216 related articles for article (PubMed ID: 25917796)
1. UbcH10 expression can predict prognosis and sensitivity to the antineoplastic treatment for colorectal cancer patients.
Cacciola NA; Calabrese C; Malapelle U; Pellino G; De Stefano A; Sepe R; Sgariglia R; Quintavalle C; Federico A; Bianco A; Uchimura Bastos A; Milone M; Bellevicine C; Milone F; Carlomagno C; Selvaggi F; Troncone G; Fusco A; Pallante P
Mol Carcinog; 2016 May; 55(5):793-807. PubMed ID: 25917796
[TBL] [Abstract][Full Text] [Related]
2. Association of clinicopathological features with UbcH10 expression in colorectal cancer.
Chen S; Chen Y; Hu C; Jing H; Cao Y; Liu X
J Cancer Res Clin Oncol; 2010 Mar; 136(3):419-26. PubMed ID: 19779934
[TBL] [Abstract][Full Text] [Related]
3. ATM mutations and E-cadherin expression define sensitivity to EGFR-targeted therapy in colorectal cancer.
Geißler AL; Geißler M; Kottmann D; Lutz L; Fichter CD; Fritsch R; Weddeling B; Makowiec F; Werner M; Lassmann S
Oncotarget; 2017 Mar; 8(10):17164-17190. PubMed ID: 28199979
[TBL] [Abstract][Full Text] [Related]
4. UbcH10 overexpression in human lung carcinomas and its correlation with EGFR and p53 mutational status.
Pallante P; Malapelle U; Berlingieri MT; Bellevicine C; Sepe R; Federico A; Rocco D; Galgani M; Chiariotti L; Sanchez-Cespedes M; Fusco A; Troncone G
Eur J Cancer; 2013 Mar; 49(5):1117-26. PubMed ID: 23102841
[TBL] [Abstract][Full Text] [Related]
5. Lauric acid can improve the sensitization of Cetuximab in KRAS/BRAF mutated colorectal cancer cells by retrievable microRNA-378 expression.
Weng WH; Leung WH; Pang YJ; Hsu HH
Oncol Rep; 2016 Jan; 35(1):107-16. PubMed ID: 26496897
[TBL] [Abstract][Full Text] [Related]
6. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
Di Nicolantonio F; Martini M; Molinari F; Sartore-Bianchi A; Arena S; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
J Clin Oncol; 2008 Dec; 26(35):5705-12. PubMed ID: 19001320
[TBL] [Abstract][Full Text] [Related]
7. UbcH10 expression provides a useful tool for the prognosis and treatment of non-small cell lung cancer.
Zhao L; Jiang L; Wang L; He J; Yu H; Sun G; Chen J; Xiu Q; Li B
J Cancer Res Clin Oncol; 2012 Nov; 138(11):1951-61. PubMed ID: 22760214
[TBL] [Abstract][Full Text] [Related]
8. UbcH10 overexpression increases carcinogenesis and blocks ALLN susceptibility in colorectal cancer.
Li SZ; Song Y; Zhang HH; Jin BX; Liu Y; Liu WB; Zhang XD; Du RL
Sci Rep; 2014 Nov; 4():6910. PubMed ID: 25376843
[TBL] [Abstract][Full Text] [Related]
9. Combinational treatment with microRNA‑133b and cetuximab has increased inhibitory effects on the growth and invasion of colorectal cancer cells by regulating EGFR.
Zhou J; Lv L; Lin C; Hu G; Guo Y; Wu M; Tian B; Li X
Mol Med Rep; 2015 Oct; 12(4):5407-14. PubMed ID: 26151111
[TBL] [Abstract][Full Text] [Related]
10. Cetuximab-mediated ADCC activity is correlated with the cell surface expression level of EGFR but not with the KRAS/BRAF mutational status in colorectal cancer.
Seo Y; Ishii Y; Ochiai H; Fukuda K; Akimoto S; Hayashida T; Okabayashi K; Tsuruta M; Hasegawa H; Kitagawa Y
Oncol Rep; 2014 May; 31(5):2115-22. PubMed ID: 24626880
[TBL] [Abstract][Full Text] [Related]
11. RNA interference-mediated silencing of UBCH10 gene inhibits colorectal cancer cell growth in vitro and in vivo.
Chen SM; Jiang CY; Wu JY; Liu B; Chen YJ; Hu CJ; Liu XX
Clin Exp Pharmacol Physiol; 2010 May; 37(5-6):525-9. PubMed ID: 20529090
[TBL] [Abstract][Full Text] [Related]
12. Cetuximab in the treatment of patients with colorectal cancer.
Garrett CR; Eng C
Expert Opin Biol Ther; 2011 Jul; 11(7):937-49. PubMed ID: 21557708
[TBL] [Abstract][Full Text] [Related]
13. Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations.
Lee J; Lee I; Han B; Park JO; Jang J; Park C; Kang WK
J Natl Cancer Inst; 2011 Apr; 103(8):674-88. PubMed ID: 21398618
[TBL] [Abstract][Full Text] [Related]
14. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab.
Yen LC; Uen YH; Wu DC; Lu CY; Yu FJ; Wu IC; Lin SR; Wang JY
Ann Surg; 2010 Feb; 251(2):254-60. PubMed ID: 20010090
[TBL] [Abstract][Full Text] [Related]
15. Nuclear factor-kB tumor expression predicts response and survival in irinotecan-refractory metastatic colorectal cancer treated with cetuximab-irinotecan therapy.
Scartozzi M; Bearzi I; Pierantoni C; Mandolesi A; Loupakis F; Zaniboni A; Catalano V; Quadri A; Zorzi F; Berardi R; Biscotti T; Labianca R; Falcone A; Cascinu S
J Clin Oncol; 2007 Sep; 25(25):3930-5. PubMed ID: 17761976
[TBL] [Abstract][Full Text] [Related]
16. UCN-01 enhances cytotoxicity of irinotecan in colorectal cancer stem-like cells by impairing DNA damage response.
Signore M; Buccarelli M; Pilozzi E; De Luca G; Cappellari M; Fanciulli M; Goeman F; Melucci E; Biffoni M; Ricci-Vitiani L
Oncotarget; 2016 Jul; 7(28):44113-44128. PubMed ID: 27286453
[TBL] [Abstract][Full Text] [Related]
17. Paxillin is positively correlated with the clinicopathological factors of colorectal cancer, and knockdown of Paxillin improves sensitivity to cetuximab in colorectal cancer cells.
Du C; Wang X; Zhang J; Liu X; Zhu J; Liu Y
Oncol Rep; 2016 Jan; 35(1):409-17. PubMed ID: 26530439
[TBL] [Abstract][Full Text] [Related]
18. Exploratory biomarker analysis for treatment response in KRAS wild type metastatic colorectal cancer patients who received cetuximab plus irinotecan.
Kim ST; Ahn TJ; Lee E; Do IG; Lee SJ; Park SH; Park JO; Park YS; Lim HY; Kang WK; Kim SH; Lee J; Kim HC
BMC Cancer; 2015 Oct; 15():747. PubMed ID: 26486455
[TBL] [Abstract][Full Text] [Related]
19. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
László L
Magy Onkol; 2010 Dec; 54(4):383-94. PubMed ID: 21163770
[TBL] [Abstract][Full Text] [Related]
20. Circulating tumor cells as a longitudinal biomarker in patients with advanced chemorefractory, RAS-BRAF wild-type colorectal cancer receiving cetuximab or panitumumab.
Musella V; Pietrantonio F; Di Buduo E; Iacovelli R; Martinetti A; Sottotetti E; Bossi I; Maggi C; Di Bartolomeo M; de Braud F; Daidone MG; Cappelletti V
Int J Cancer; 2015 Sep; 137(6):1467-74. PubMed ID: 25704501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
